Influence of the implantation site on the sensitivity of patient pancreatic tumor xenografts to Apo2L/TRAIL therapy

Pancreas

Volumn 43, Issue 2, 2014, Pages 298-305

  Sharma, Rohit ^a,d   Buitrago, Sandra ^b   Pitoniak, Rose ^c   Gibbs, John F ^a,e   Curtin, Leslie ^b   Seshadri, Mukund ^c   Repasky, Elizabeth A ^c   Hylander, Bonnie L ^c  

^a Department of Surgical Oncology ^*  (United States)

^b Laboratory Animal Resources   (United States)

^c ROSWELL PARK CANCER INSTITUTE   (United States)

^d Lehigh Valley Physician Group   (United States)

^e UNIVERSITY AT BUFFALO   (United States)

Author keywords

Apo2L TRAIL; implantation site; metastatic model; patient pancreatic tumor xenograft

Indexed keywords

ANIMALS; HETEROGRAFTS; HUMANS; MAGNETIC RESONANCE IMAGING; MICE; MICE, SCID; NEOPLASM METASTASIS; ORGAN SIZE; PANCREAS; PANCREATIC NEOPLASMS; SUBCUTANEOUS TISSUE; SURVIVAL ANALYSIS; TIME FACTORS; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TRANSPLANTATION, HETEROLOGOUS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84894479196     PISSN: 08853177     EISSN: 15364828     Source Type: Journal    
DOI: 10.1097/MPA.0000000000000099     Document Type: Article

References (37)

1. Richmond A, Su Y. Mouse xenograft models vs GEM models for human cancer therapeutics. Dis Model Mech. 2008;1:78-82.
2. Francia G, Kerbel RS. Raising the bar for cancer therapy models. Nat Biotechnol. 2010;28:561-562.
3. Killion JJ, Radinsky R, Fidler IJ. Orthotopic models are necessary to predict therapy of transplantable tumors in mice. Cancer Metastasis Rev. 1999;17:279-284.
4. Ashkenazi A, Holland P, Eckhardt SG. Ligand-based targeting of apoptosis in cancer: the potential of recombinant human apoptosis ligand 2/tumor necrosis factor-related apoptosis-inducing ligand (rhApo2L/TRAIL). J Clin Oncol. 2008;26:3621-3630.
5. Hylander BL, Pitoniak R, Penetrante RB, et al. The anti-tumor effect of Apo2L/TRAIL on patient pancreatic adenocarcinomas grown as xenografts in SCID mice. J Transl Med. 2005;3:22.
6. Herbst RS, Eckhardt SG, Kurzrock R, et al. Phase I dose-escalation study of recombinant human Apo2L/TRAIL, a dual proapoptotic receptor agonist, in patients with advanced cancer. J Clin Oncol. 2010;28:2839-2846.
7. Gonzalvez F, Ashkenazi A. New insights into apoptosis signaling by Apo2L/TRAIL. Oncogene. 2010;29:4752-4765.
8. Hotte SJ, Hirte HW, Chen EX, et al. A phase 1 study of mapatumumab (fully human monoclonal antibody to TRAIL-R1) in patients with advanced solid malignancies. Clin Cancer Res. 2008;14:3450-3455.
9. Wiezorek J, Holland P, Graves J. Death receptor agonists as a targeted therapy for cancer. Clin Cancer Res. 2010;16:1701-1708.
10. Fu X, Guadagni F, Hoffman RM. A metastatic nude-mouse model of human pancreatic cancer constructed orthotopically with histologically intact patient specimens. Proc Natl Acad Sci U S A. 1992;89:5645-5649.
11. Kim MP, Evans DB, Wang H, et al. Generation of orthotopic and heterotopic human pancreatic cancer xenografts in immunodeficient mice. Nat Protoc. 2009;4:1670-1680.
12. Trauzold A, Siegmund D, Schniewind B, et al. TRAIL promotes metastasis of human pancreatic ductal adenocarcinoma. Oncogene. 2006;25:7434-7439.
13. Rubio-Viqueira B, Jimeno A, Cusatis G, et al. An in vivo platform for translational drug development in pancreatic cancer. Clin Cancer Res. 2006;12:4652-4661.
14. Sakakibara T, Xu Y, Bumpers HL, et al. Growth and metastasis of surgical specimens of human breast carcinomas in SCID mice. Cancer J Sci Am. 1996;2:291-300.
15. Seshadri M, Merzianu M, Tang H, et al. Establishment and characterization of patient tumor-derived head and neck squamous cell carcinoma xenografts. Cancer Biol Ther. 2009;8:2275-2283.
16. Silver DF, Hempling RE, Piver MS, et al. Effects of IL-12 on human ovarian tumors engrafted into SCID mice. Gynecol Oncol. 1999;72:154-160.
17. Xu Y, Silver DF, Yang NP, et al. Characterization of human ovarian carcinomas in a SCID mouse model. Gynecol Oncol. 1999;72:161-170.
18. Naka T, Sugamura K, Hylander BL, et al. Effects of tumor necrosis factor-related apoptosis-inducing ligand alone and in combination with chemotherapeutic agents on patients' colon tumors grown in SCID mice. Cancer Res. 2002;62:5800-5806.
19. Sugamura K, Gibbs JF, Belicha-Villanueva A, et al. Synergism of CPT-11 and Apo2L/TRAIL against two differentially sensitive human colon tumor xenografts. Oncology. 2008;74:188-197.
20. Jin H, Yang R, Fong S, et al. Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand cooperates with chemotherapy to inhibit orthotopic lung tumor growth and improve survival. Cancer Res. 2004;64:4900-4905.
21. Jin H, Yang R, Ross J, et al. Cooperation of the agonistic DR5 antibody apomab with chemotherapy to inhibit orthotopic lung tumor growth and improve survival. Clin Cancer Res. 2008;14:7733-7740.
22. Malin D, Chen F, Schiller C, et al. Enhanced metastasis suppression by targeting TRAIL receptor 2 in a murine model of triple-negative breast cancer. Clin Cancer Res. 2011;17:5005-5015.
23. Bruns CJ, Harbison MT, Kuniyasu H, et al. In vivo selection and characterization of metastatic variants from human pancreatic adenocarcinoma by using orthotopic implantation in nude mice. Neoplasia. 1999;1:50-62.
24. Lee NC, Bouvet M, Nardin S, et al. Antimetastatic efficacy of adjuvant gemcitabine in a pancreatic cancer orthotopic model. Clin Exp Metastasis. 2000;18:379-384.
25. Loukopoulos P, Kanetaka K, Takamura M, et al. Orthotopic transplantation models of pancreatic adenocarcinoma derived from cell lines and primary tumors and displaying varying metastatic activity. Pancreas. 2004;29:193-203.
26. Feldmann G, Dhara S, Fendrich V, et al. Blockade of hedgehog signaling inhibits pancreatic cancer invasion and metastases: a new paradigm for combination therapy in solid cancers. Cancer Res. 2007;67:2187-2196.
27. Cruz-Munoz W, Man S, Kerbel RS. Effective treatment of advanced human melanoma metastasis in immunodeficient mice using combination metronomic chemotherapy regimens. Clin Cancer Res. 2009;15:4867-4874.
28. Ashkenazi A, Pai RC, Fong S, et al. Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest. 1999;104:155-162.
29. Walczak H, Miller RE, Ariail K, et al. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med. 1999;5:157-163.
30. Bossen C, Ingold K, Tardivel A, et al. Interactions of tumor necrosis factor (TNF) and TNF receptor family members in the mouse and human. J Biol Chem. 2006;281:13964-13971.
31. Wilson NS, Yang A, Yang B, et al. Proapoptotic activation of death receptor 5 on tumor endothelial cells disrupts the vasculature and reduces tumor growth. Cancer Cell. 2012;22:80-90.
32. Cook N, Jodrell DI, Tuveson DA. Predictive in vivo animal models and translation to clinical trials. Drug Discov Today. 2012;17:253-260.
33. Mazur PK, Siveke JT. Genetically engineered mouse models of pancreatic cancer: unravelling tumour biology and progressing translational oncology. Gut. 2012;61:1488-1500.
34. Johnstone RW, Frew AJ, Smyth MJ. The TRAIL apoptotic pathway in cancer onset, progression and therapy. Nat Rev Cancer. 2008;8:782-798.
35. Singh M, Lima A, Molina R, et al. Assessing therapeutic responses in Kras mutant cancers using genetically engineered mouse models. Nat Biotechnol. 2010;28:585-593.
36. Singh M, Murriel CL, Johnson L. Genetically engineered mouse models: closing the gap between preclinical data and trial outcomes. Cancer Res. 2012;72:2695-2700.
37. Olive KP, Jacobetz MA, Davidson CJ, et al. Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science. 2009;324:1457-1461.